There is a growing literature exploring the placebo response within specific mental
disorders, but no overarching quantitative synthesis of this research has analyzed evidence …

Background The mechanisms underlying placebo effects of psychotropic drugs remain
poorly understood. We carried out the first, to our knowledge, systematic review of functional …

Background The efficacy of esketamine in treatment-resistant depression (TRD) has been
confirmed. However, its administration is expensive and restrictive, with limited knowledge …

Neurotechnologies that measure and modulate brain activity have not yet reached
widespread clinical relevance. To accelerate translation into patient care, we propose three …

Over the past decade there has been a surge in interest in placebo-controlled trials using
non-classical 3, 4-methylenedioxymethamphetamine (MDMA) and classical psychedelics …

Background Anxiety disorders are highly prevalent and socio-economically costly. Novel
pharmacological treatments for these disorders are needed because many patients do not …

Introduction Given the high prevalence of mental health disorders and their significant
socioeconomic burden, there is a need to develop improved treatments, and to evaluate …

BackgroundDespite the prevalence of antidepressant-related sexual side effects,
comparisons of treatments for these problematic side effects are lacking. MethodsTo …

Improvement or benefit in a patient treated with a placebo is a placebo response and
worsening or adverse effects in a patient treated with a placebo is a nocebo response. Both …

Gambling disorder creates a significant public health burden. Despite decades of clinical
trials, there are no licensed pharmacological treatments for gambling disorder. Contributing …